Short-Chain Carbon Sources

Challa, Azariyas A.; Lewandowski, E. Douglas

doi:10.1016/j.jacbts.2021.12.010

Cited by 13 publications

(6 citation statements)

References 121 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Ранее в других работах было описано численное снижение представленности Faecalibacterium prausnitzii у пациентов с КБС и СН [12,13]. В совокупности эти данные согласуются с тем фактом, что данная бактерия продуцирует бутират, который препятствует развитию гипертрофии кардиомиоцитов, уменьшает воспаление и фиброз миокарда, снижает апоптоз и продукцию активных форм кислорода [14,15].…”

Section: ассоциации между численностью некоторых пред ставителей км и...unclassified

Gut microbiota at different stages of cardiovascular disease continuum

Yafarova,

Dementyeva,

Zlobovskaya

et al. 2024

Cardiovasc Ther Prev

View full text Add to dashboard Cite

Aim. To study the relationship of gut microbiota (GM) composition with clinical and paraclinical characteristics of patients with coronary artery disease (CAD) and heart failure with reduced ejection fraction (HFrEF).Material and methods. The study included 64 patients (men, 71,9%) with CAD, 33 (men, 87,9%) with HFrEF and 38 (men, 63,2%) with various cardiovascular risk factors (control group). GM composition was assessed using real-time polymerase chain reaction and next- generation sequencing. To identify correlations of GM composition with clinical and paraclinical characteristics, the Spearman rank correlation coefficient (ρ) was calculated. Generalized linear models (QuasiPoisson, overdispersion) with covariates (age, body mass index) were used to compare groups by phylotype.Results. The relative abundance of Bacillota phylotypes is significantly higher in patients with CAD and HFrEF compared to controls (p<0,001). The Bacillota/Bacteroidota dysbiosis ratio was also significantly higher in patients with CAD and HFrEF than in the control group (p<0,001). According to correlation analysis, the relative representation of methanogenic archaea Methanomassiliicoccaceae, Methanomethylophilaceae (ρ=0,49, p<0,0003) directly correlated with ventricular arrhythmias in patients with HFrEF.Conclusion. Patients with CAD and HFrEF differ significantly from the control group in GM composition at the phylotype level. In the study groups, Bacillota/Bacteroidota dysbiosis ratio was also significantly higher than in the control group. The relative abundance of the archaea Methanomassiliicoccaceae and Methanomethylophilaceae is associated with episodes of ventricular tachycardia/ventricular fibrillation.

show abstract

Section: ассоциации между численностью некоторых пред ставителей км и...unclassified

Gut microbiota at different stages of cardiovascular disease continuum

Yafarova,

Dementyeva,

Zlobovskaya

et al. 2024

Cardiovasc Ther Prev

View full text Add to dashboard Cite

show abstract

“…Так, установлено, что β-гидроксибутират оказывает несколько гемодинамических эффектов, включая снижение периферического сосудистого сопротивления и давления наполнения, умеренное увеличение частоты сердечных сокращений и увеличение сердечного выброса. Кроме того, он может оказывать противовоспалительное действие за счет ингибирования воспаления и снижения продукции воспалительных цитокинов [26].…”

Section: улучшение сердечного энергетического метаболизмаunclassified

Sodium-glucose cotransporter 2 inhibitors: mechanisms of cardiorenal protection: A review

Leonova

2024

Consilium Medicum

View full text Add to dashboard Cite

Sodium-glucose cotransporter 2 inhibitors (SGLT-2) are a new class of hypoglycemic drugs that were initially approved for the treatment of type 2 diabetes. Currently, 5 drugs in the SGLT-2 class of drugs are approved by the FDA for glycemic control: canagliflozin, dapagliflozin, empagliflozin, ertugliflozin and sotagliflozin. However, their effectiveness in reducing the risk of heart failure and progression of chronic kidney disease was soon established, regardless of diabetes status. In addition, according to a number of meta-analyses of RCTs in patients with cardiometabolic and renal diseases, the use of SGLT-2 reduces cardiovascular and overall mortality and the number of serious adverse cardiac events and renal outcomes in patients with or without diabetes, which is reflected in the indications to their use. Scientific data are presented in a discussion of the mechanisms of cardioprotective and renoprotective effects of the SGLT-2 class, many of which are considered as pleiotropic effects not related to the effect on glycemic levels.

show abstract

“…The consequences of butyrate as a signaling metabolite should be explored further, as should the effects of other short-chain fuels, such as octanoate, as ancillary cardiac fuels during HF. 143…”

Section: The Potential For Ketone Therapeutics: Rationale and Implica...mentioning

confidence: 99%

Ketones and the Heart: Metabolic Principles and Therapeutic Implications

Matsuura

Puchalska

Crawford

et al. 2023

Circulation Research

View full text Add to dashboard Cite

The ketone bodies beta-hydroxybutyrate and acetoacetate are hepatically produced metabolites catabolized in extrahepatic organs. Ketone bodies are a critical cardiac fuel and have diverse roles in the regulation of cellular processes such as metabolism, inflammation, and cellular crosstalk in multiple organs that mediate disease. This review focuses on the role of cardiac ketone metabolism in health and disease with an emphasis on the therapeutic potential of ketosis as a treatment for heart failure (HF). Cardiac metabolic reprogramming, characterized by diminished mitochondrial oxidative metabolism, contributes to cardiac dysfunction and pathologic remodeling during the development of HF. Growing evidence supports an adaptive role for ketone metabolism in HF to promote normal cardiac function and attenuate disease progression. Enhanced cardiac ketone utilization during HF is mediated by increased availability due to systemic ketosis and a cardiac autonomous upregulation of ketolytic enzymes. Therapeutic strategies designed to restore high-capacity fuel metabolism in the heart show promise to address fuel metabolic deficits that underpin the progression of HF. However, the mechanisms involved in the beneficial effects of ketone bodies in HF have yet to be defined and represent important future lines of inquiry. In addition to use as an energy substrate for cardiac mitochondrial oxidation, ketone bodies modulate myocardial utilization of glucose and fatty acids, two vital energy substrates that regulate cardiac function and hypertrophy. The salutary effects of ketone bodies during HF may also include extra-cardiac roles in modulating immune responses, reducing fibrosis, and promoting angiogenesis and vasodilation. Additional pleotropic signaling properties of beta-hydroxybutyrate and AcAc are discussed including epigenetic regulation and protection against oxidative stress. Evidence for the benefit and feasibility of therapeutic ketosis is examined in preclinical and clinical studies. Finally, ongoing clinical trials are reviewed for perspective on translation of ketone therapeutics for the treatment of HF.

show abstract

Short-Chain Carbon Sources

Cited by 13 publications

References 121 publications

Gut microbiota at different stages of cardiovascular disease continuum

Gut microbiota at different stages of cardiovascular disease continuum

Sodium-glucose cotransporter 2 inhibitors: mechanisms of cardiorenal protection: A review

Ketones and the Heart: Metabolic Principles and Therapeutic Implications

Contact Info

Product

Resources

About